End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.26 NZD | +0.71% | -4.27% | -27.80% |
Apr. 22 | New Zealand Shares Jumps on Business Optimism; Ryman Healthcare CEO Resigns | MT |
Apr. 21 | Ryman Healthcare Group CEO Resigns | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-27.80% | 1.72B | B | ||
-14.17% | 86.34B | B- | ||
+17.86% | 84.49B | C+ | ||
+10.92% | 29.68B | C+ | ||
-8.51% | 17.5B | B | ||
-2.67% | 16.67B | A- | ||
-0.24% | 15.18B | A- | ||
-3.63% | 12.71B | A- | ||
+2.63% | 12.53B | A- | ||
-30.53% | 11.89B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RYM Stock
- Ratings Ryman Healthcare Limited